This reports provides a data-driven overview of the current and future competitive landscape in POP therapeutics.
In 2024, more than 34,000,000 incident cases of POP are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for POP.
Most marketed drugs for POP are enzyme inhibitors, followed by receptor agonists, by mechanism of action.
Phase III pipeline for POP is robust and includes 27 drugs, while pre-registration comprises four drugs.
Approximately 39.34% of the clinical trials initiated over the last 10 years for POP have been conducted in sites across Asia-Pacific.
Acquisitions were the most prevalent deal type in North America, Europe, and Asia-Pacific.
Scope
GlobalData’s POP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the POP market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global POP market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Report Scope
Abbreviations
Key Findings
Disease Overview
Disease Etiology
Epidemiology Overview
Epidemiology Overview - Incident Cases of POP in 2024 and 2028
Treatment Overview
Treatment Guidelines
Management Algorithm - Multimodal Pain Control in POP for Hand Surgery
Marketed Drugs Assessment
Marketed Drugs - Leading Marketed Drugs in POP
Marketed Drugs - Overview by Mechanism of Action
Marketed Drug Profile - Heron Therapeutics's Zynrelef
Marketed Drug Profile - Hyloris Pharmaceuticals's Combogesic
Marketed Drug Profile - Sino Biopharmaceutical's Kaifen
Marketed Drug Profile - Merck's Hetori
Marketed Drug Profile - Daiichi Sankyo's Loxonin
Marketed Drug Profile - Mundipharma's OxyNorm/Endain
Marketed Drug Profile - Rayner Intraocular Lenses's Omidria
Marketed Drug Profile - B. Braun Melsungen's Ameniflac
Marketed Drug Profile - Jiangsu Hengrui Medicine's Bupivacaine
Marketed Drug Profile - Innocoll Holding's Xaracoll
Marketed Drug Profile - DURECT Corp's Posimir
Marketed Drug Profile - Jiangsu Hengrui Medicine's Aisut
Marketed Drug Profile - Cristalia Produtos Quimicos Farmaceutico's Fentanest Bolsa
Marketed Drug Profile - Halex Istar Industria Farmaceutica's Axiflennid
Marketed Drug Profile - Juno Pharmaceutical/Halex Istar Industria Farmaceutica's Naproxen
Marketed Drug Profile - Johnson & Johnson's Dolormin Duro/Motrimax
Marketed Drug Profile - Trevena's Olinvyk
Marketed Drug Profile - Talphera's Zalviso
Pricing and Reimbursement Assessment
Marketed Drugs - Annual Cost of Therapy
Pipeline Drugs Assessment
Pipeline Drugs Overview - Late-Stage Pipeline Drugs in POP
Pipeline Drugs - Overview by Development Stage
Pipeline Drugs - Overview by Mechanism of Action
Pipeline Drugs - Overview by Molecule Type
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in POP
Pipeline Drugs - Phase Transition Success Rate and Likelihood of Approval in CNS & POP
Clinical Trials Assessment
Clinical Trials in POP - Historical Overview
Clinical Trials in POP - Overview by Phase
Clinical Trials in POP - Overview by Status
Clinical Trials in POP - Overview by Phase for Ongoing and Planned Trials
Clinical Trials in POP - Trials with a Virtual Component
Clinical Trials in POP - Geographic Overview
Clinical Trials in POP - Single-Country and Multinational Trials by Region
Clinical Trials in POP - Top 20 Sponsors with Breakdown by Phase
Clinical Trials in POP - Top 20 Commercial Sponsors with Breakdown by Phase
Clinical Trials in POP - Top 20 Sponsors with Breakdown by Status
Clinical Trials in POP - Top 20 Commercial Sponsors with Breakdown by Status
Clinical Trials in POP - Overview by Endpoint Status
Clinical Trials in POP - Overview by Race and Ethnicity
Clinical Trials in POP - Enrollment Data
Clinical Trials in POP - Overview of Sites by Geography
Clinical Trials in POP - Top 20 Countries for Trial Sites